Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload

British Journal of Haematology

Volumn 147, Issue 5, 2009, Pages 752-759

  Taher, Ali ^a   Cappellini, Maria D ^b   Vichinsky, Elliott ^c   Galanello, Renzo ^d   Piga, Antonio ^e   Lawniczek, Tomasz ^f   Clark, Joan ^f   Habr, Dany ^f   Porter, John B ^g  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^b UNIVERSITY OF MILAN   (Italy)

^c CHILDREN S HOSPITAL OAKLAND   (United States)

^d UNIVERSITY OF CAGLIARI   (Italy)

^e UNIVERSITY OF TURIN   (Italy)

^f NOVARTIS PHARMA AG   (Switzerland)

^g UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Deferasirox; Efficacy; Safety; Transfusion dependent

Indexed keywords

DEFERASIROX; FERRITIN; IRON;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ADOLESCENT; ADULT; ARTICLE; BETA THALASSEMIA; CATARACT; CHILD; CHOLECYSTITIS; CHOLELITHIASIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE URINE LEVEL; DIARRHEA; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EYE EXAMINATION; FEMALE; FERRITIN BLOOD LEVEL; GASTRITIS; GASTROINTESTINAL HEMORRHAGE; HEARING; HEARING LOSS; HEART FAILURE; HUMAN; HYPOTENSION; IRON INTAKE; IRON OVERLOAD; KIDNEY FUNCTION; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; NAUSEA; OBSTRUCTIVE JAUNDICE; PANCREATITIS; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN URINE LEVEL; SCHOOL CHILD; SICKLE CELL ANEMIA; SIDE EFFECT; VISUAL ACUITY; VISUAL IMPAIRMENT; VOMITING;

ADOLESCENT; ADULT; ANEMIA; BENZOIC ACIDS; BLOOD TRANSFUSION; CHILD; CHILD, PRESCHOOL; CREATININE; DRUG ADMINISTRATION SCHEDULE; FEMALE; FERRITINS; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TRIAZOLES; YOUNG ADULT;

EID: 70449403619     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2009.07908.x     Document Type: Article

References (13)

1. Brownell, A., Lowson, S. Brozovic, M. (1986) Serum ferritin concentration in sickle cell crisis. Journal of Clinical Pathology, 39, 253 255.
2. Cappellini, M.D., Cohen, A., Piga, A., Bejaoui, M., Perrotta, S., Agaoglu, L., Aydinok, Y., Kattamis, A., Kilinc, Y., Porter, J., Capra, M., Galanello, R., Fattoum, S., Drelichman, G., Magnano, C., Verissimo, M., Athanassiou-Metaxa, M., Giardina, B., Kourakli-Symeonidis, A., Janka-Schaub, G., Coates, T., Vermylen, C., Olivieri, N., Thuret, I., Opitz, H., Ressayre-Djaffer, C., Marks, P. Alberti, D. (2006) A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with β-thalassemia. Blood, 107, 3455 3462.
3. Cohen, A.R., Glimm, E. Porter, J.B. (2008) Effect of transfusional iron intake on response to chelation therapy in β-thalassemia major. Blood, 111, 583 587.
4. Galanello, R., Piga, A., Forni, G.L., Bertrand, Y., Foschini, M.L., Bordone, E., Leoni, G., Lavagetto, A., Zappu, A., Longo, F., Maseruka, H., Latham, N., Sechaud, R., Belleli, R. Alberti, D. (2006) Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in paediatric patients with β-thalassaemia major. Haematologica, 91, 1343 1351.
5. Nisbet-Brown, E., Olivieri, N.F., Giardina, P.J., Grady, R.W., Neufeld, E.J., Séchaud, R., Krebs-Brown, A.J., Anderson, J.R., Alberti, D., Sizer, K.C. Nathan, D.G. (2003) Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet, 361, 1597 1602.
6. Olivieri, N.F. Brittenham, G.M. (1997) Iron-chelating therapy and the treatment of thalassemia. Blood, 89, 739 761.
7. Olivieri, N.F., Nathan, D.G., MacMillan, J.H., Wayne, A.S., Liu, P.P., McGee, A., Martin, M., Koren, G. Cohen, A.R. (1994) Survival in medically treated patients with homozygous β-thalassemia. New England Journal of Medicine, 331, 574 578.
8. Piga, A., Galanello, R., Forni, G.L., Cappellini, M.D., Origa, R., Zappu, A., Donato, G., Bordone, E., Lavagetto, A., Zanaboni, L., Sechaud, R., Hewson, N., Ford, J.M., Opitz, H. Alberti, D. (2006) Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica, 91, 873 880.
9. ®, ICL670). Blood, 110, abstract 2778.
10. Porter, J., Galanello, R., Saglio, G., Neufeld, E.J., Vichinsky, E., Cappellini, M.D., Olivieri, N., Piga, A., Cunningham, M.J., Soulières, D., Gattermann, N., Tchernia, G., Maertens, J., Giardina, P., Kwiatkowski, J., Quarta, G., Jeng, M., Forni, G.L., Stadler, M., Cario, H., Debusscher, L., Della Porta, M., Cazzola, M., Greenberg, P., Alimena, G., Rabault, B., Gathmann, I., Ford, J.M., Alberti, D. Rose, C. (2008) Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. European Journal of Haematology, 80, 168 176.
11. Taher, A., El-Beshlawy, A., Elalfy, M.S., Al Zir, K., Daar, S., Damanhouri, G., Habr, D., Kriemler-Krahn, U., Hmissi, A. Al Jefri, A. (2009) Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia: the ESCALATOR study. European Journal of Haematology, 82, 458 465.
12. Thalassaemia International Federation 2008) Guidelines for the clinical management of thalassaemia, 2nd Revised Edition. Available at: http://www.thalassaemia.org.cy/pdf/Guidelines-2nd-revised-edition-EN.pdf. Accessed on 9 Sept 2009.
13. Vichinsky, E., Onyekwere, O., Porter, J., Swerdlow, P., Eckman, J., Lane, P., Files, B., Hassell, K., Kelly, P., Wilson, F., Bernaudin, F., Forni, G.L., Okpala, I., Ressayre-Djaffer, C., Alberti, D., Holland, J., Marks, P., Fung, E., Fischer, R., Mueller, B.U. Coates, T. (2007) A randomized comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. British Journal of Haematology, 136, 501 508.